agilon health, inc.
agilon Health partners with community-based physician groups to support Medicare-focused, value-based care for seniors. Its platform provides technology, people, processes and capital, while long-term partnerships help physician groups manage the total healthcare needs of attributed patients. The company typically forms wholly owned risk-bearing entities in local geographies. These entities contract with health plan payors for monthly per-member payments to manage covered medical costs, and with physician groups to provide care. agilon earns capitation payments and shares savings with physician partners when care quality improves and costs are reduced. The company’s network includes 28 anchor physician groups across 30 geographies as of December 31, 2025, and supports Medicare Advantage members and traditional Medicare beneficiaries through ACO REACH and the Medicare Shared Savings Program. Its proprietary systems include the CORE technology platform, HCC Manager software and Minerva clinical data platform. agilon is headquartered in Westerville, Ohio.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AGL in the last 30 days.
See all $AGL insider activity →Wells Fargo raised its price target for Agilon Health to $170 from $146, maintaining an Overweight rating. This implies a 54.1% upside from the Nov 12 close of $110.30.
StoneX raised its price target for Agilon Health (NYSE:AGL) to $145 from $140, maintaining a Buy rating. The company increased its fiscal 2026 AEBITDA guidance to $145M-$155M, up from $85M. Agilon's Q3 2026 earnings of $1.97 per share beat estimates, with revenue at $1.51B. The stock has gained 634% over the past year, trading at $113.86.
Evercore ISI Group kept Agilon Health's rating at In-Line but raised its price target to $105 from $95, suggesting a 9.1% upside from the Nov 4 close of $96.23.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AGL (agilon health, inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent AGL coverage spans financial news, earnings and market movers.
Wells Fargo raised its price target for Agilon Health to $170 from $146, maintaining an Overweight rating. This implies a 54.1% upside from the Nov 12 close of $110.30.
The upgraded guidance and higher price target suggest potential upside for AGL.
Evercore ISI Group kept Agilon Health's rating at In-Line but raised its price target to $105 from $95, suggesting a 9.1% upside from the Nov 4 close of $96.23.
Strong earnings beat and raised guidance suggest upside momentum.
Guidance raised reflects stronger Q3 performance, likely supporting the stock price
AlphAI scores every news story that mentions AGL with an AI model for sentiment and relevance, and aggregates insider trades from agilon health, inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo raised its price target for Agilon Health to $170 from $146, maintaining an Overweight rating. This implies a 54.1% upside from the Nov 12 close of $110.30.
StoneX raised its price target for Agilon Health (NYSE:AGL) to $145 from $140, maintaining a Buy rating. The company increased its fiscal 2026 AEBITDA guidance to $145M-$155M, up from $85M. Agilon's Q3 2026 earnings of $1.97 per share beat estimates, with revenue at $1.51B. The stock has gained 634% over the past year, trading at $113.86.
Evercore ISI Group kept Agilon Health's rating at In-Line but raised its price target to $105 from $95, suggesting a 9.1% upside from the Nov 4 close of $96.23.
Agilon Health (NYSE:AGL) reported Q3 2026 revenue of $1.52 billion, beating estimates by 4.2%. EPS and EBITDA also exceeded expectations. The company raised full-year revenue guidance to $5.88 billion and EBITDA guidance to $150 million. Operating margin improved to 1.6%, and customer count increased to 566,000.
agilon health, inc. (AGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 agilon health Reports Third Quarter 2026 Results Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year Increases Full Year 2026 Guidance to Reflect Positive Third Quarter Results Westerville, O.H., November 4, 2026 – agilon health, inc.
ADARx (ADRX) priced its IPO at $17/share, raising $446.3M, with AbbVie investing $100M. CNSY (CNSY) secured reimbursement with Blue Cross Blue Shield. JAGX (JAGX) completed a reverse stock split. AGL (AGL) expanded its partnership with Springfield Clinic. ONCO (ONCO) agreed to acquire Realbotix. All stocks traded higher.
Dave & Buster's (PLAY) fell 11.1% due to Q2 earnings miss. Vishay (VSH) rose 2.5% on Oppenheimer's Outperform rating. DocuSign (DOCU) gained 3.9% after IDC recognition and AI news. SentinelOne (S) rose 2.9% on Latio's AI Security Platform Leader status. Agilon Health (AGL) climbed 3.9% after Bernstein SocGen's upgrade and price target raise.
Agilon Health (AGL) shares rose 3.9% after Bernstein upgraded the stock to Outperform and raised its price target to $125 from $86, citing improvements in risk management and cost control. The stock later settled at $94.74, up 2.8%. AGL is up 463% YTD but still 27% below its 52-week high.
Analysts made several calls on Tuesday, including upgrades for Nokia (NOK), The New York Times (NYT), Agilon (AGL), and Eli Lilly (LLY). Price targets were raised for NYT ($82), AGL ($125), and Palantir (PLTR, $250). Other notable actions include initiations on Janus Living, Vishay Intertechnology (VSH), and Samsara (IOT).
The article highlights Q2 results for outpatient and specialty care firms. Surgery Partners (SGRY) reported slowest revenue growth and weaker full-year guidance, with the stock down 1.4% to $15.32. LifeStance (LFST) revenue rose to $435.4M (+26.1%) and shares rose 18.3% to $12.27. U.S. Physical Therapy (USPH) revenue $214.1M (+8.5%) and shares $81.96. Encompass Health (EHC) revenue $1.60B (+9.6%) and shares $124.69. agilon health (AGL) revenue $1.49B (+7.2%), shares $87.56.
